Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CROSSWALK-c: crovalimab for prevention of vaso-occlusive episodes in sickle cell disease
PACTR202308685033448Phase 2Recruiting
- Sponsor
- Roche
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of crovalimab in sickle cell disease (SCD), sponsored by Roche. Primary endpoint: Annualized rate of medical facility vaso-occlusive episodes. Started Mar 2022; status: recruiting.
02
Drugs
crovalimab
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202308685033448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202308685033448.